FDG-PET/CT in the staging of local/regional metastases in breast cancer

被引:54
作者
Robertson, Ian J. [1 ]
Hand, Fiona [1 ]
Kell, Malcolm R. [1 ]
机构
[1] Mater Misericordiae Univ Hosp, Eccles Breast Screening Unit, Dublin 7, Ireland
关键词
FDG-PET/CT; Breast cancer; Local/regional metastases; POSITRON-EMISSION-TOMOGRAPHY; LYMPH-NODE BIOPSY; MANAGEMENT; SCAN;
D O I
10.1016/j.breast.2011.07.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is the commonest female malignancy in the Western world and the most reliable predictor for survival is axillary lymph node metastases. Conventional staging techniques employed in breast cancer include mammography, ultrasonography, isotope bone scanning, sentinel lymph node biopsy, axillary lymph node dissection and magnetic resonance imaging. More recently FDG-PET and FDG-PET/CT have been used to complement the above methods. This review assesses the role of FOG-PET/CT in axillary staging ill patients with primary breast cancer. A PubMed search was conducted and all articles containing relevant or new information were included. Relevant studies examined identified that FOG-PET/CT has a sensitivity of 60% and a specificity of 97% in detecting lymphatic metastasis. Although positive axillary FOG-PET/CT is a good predictor of axillary disease and correlates well with SLNB, the relatively poor sensitivity (60%) must be considered for treatment planning. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:491 / 494
页数:4
相关论文
共 50 条
  • [31] Progressive Osteoblastic Bone Metastases in Breast Cancer Negative on FDG-PET
    Huyge, Valrie
    Garcia, Camilo
    Vanderstappen, Anja
    Alexiou, Jean
    Gil, Thierry
    Flamen, Patrick
    CLINICAL NUCLEAR MEDICINE, 2009, 34 (07) : 417 - 420
  • [32] Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer
    Baun, Christina
    Falch, Kirsten
    Gerke, Oke
    Hansen, Jeanette
    Tram Nguyen
    Alavi, Abass
    Hoilund-Carlsen, Poul-Flemming
    Hildebrandt, Malene G.
    BMC MEDICAL IMAGING, 2018, 18
  • [33] 18FDG-PET/CT in staging and measuring the efficacy of neoadjuvant chemotherapy in breast cancer
    Groheux, D.
    Hindie, E.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2015, 39 (03): : 315 - 326
  • [34] FDG-PET for preoperative staging of bladder cancer
    O. Drieskens
    R. Oyen
    H. Van Poppel
    Y. Vankan
    P. Flamen
    L. Mortelmans
    European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32 : 1412 - 1417
  • [35] FDG-PET for preoperative staging of bladder cancer
    Drieskens, O
    Oyen, R
    Van Poppel, H
    Vankan, Y
    Flamen, P
    Mortelmans, L
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (12) : 1412 - 1417
  • [36] Impact of FDG-PET for staging of oesophageal cancer
    Andreas Imdahl
    M. Hentschel
    M. Kleimaier
    U. T. Hopt
    I. Brink
    Langenbeck's Archives of Surgery, 2004, 389 : 283 - 288
  • [37] Present and future role of FDG-PET/CT imaging in the management of breast cancer
    Kitajima, Kazuhiro
    Miyoshi, Yasuo
    JAPANESE JOURNAL OF RADIOLOGY, 2016, 34 (03) : 167 - 180
  • [38] A systematic review of FDG-PET in breast cancer
    Escalona, S.
    Blasco, J. A.
    Reza, M. M.
    Andradas, E.
    Gomez, N.
    MEDICAL ONCOLOGY, 2010, 27 (01) : 114 - 129
  • [39] A systematic review of FDG-PET in breast cancer
    S. Escalona
    J. A. Blasco
    M. M. Reza
    E. Andradas
    N. Gómez
    Medical Oncology, 2010, 27 : 114 - 129
  • [40] Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients
    Na Young Jung
    Ie Ryung Yoo
    Bong Joo Kang
    Sung Hun Kim
    Byung Joo Chae
    Ye Young Seo
    Breast Cancer, 2016, 23 : 141 - 148